Understanding Your Child's HLCS Diagnosis
At a Glance
Holocarboxylase synthetase (HLCS) deficiency is a rare inherited disorder that disrupts the body’s use of biotin; early, consistent oral biotin can normalize body chemistry and support healthy growth and development.
Receiving a diagnosis of Holocarboxylase Synthetase (HLCS) Deficiency can feel overwhelming, especially when it involves a condition you may never have heard of before. It is natural to feel a mix of shock, fear, and anxiety as you navigate this new information [1][2]. While this is a serious metabolic disorder, the most important thing to know is that with prompt and consistent treatment, the outcomes are often very favorable [3][4].
What is HLCS Deficiency?
HLCS deficiency is a rare genetic condition that affects how your baby’s body processes nutrients. Normally, the body uses a B-vitamin called biotin as a “key” to activate several important enzymes [5]. These enzymes act like biological tools that help break down proteins, fats, and carbohydrates from food into energy [6].
In a child with HLCS deficiency, the body cannot properly attach biotin to these enzymes [5]. Without that biotin “key,” the enzymes cannot do their jobs. This leads to a backup of certain chemicals in the blood and urine, which can cause the body to become too acidic (a state called metabolic acidosis) [6][7].
How the Diagnosis Happens
For many families, the first sign of a problem comes from a newborn screening (NBS) [8]. This is the routine heel-prick test performed shortly after birth.
- The “Flag”: The screening looks for a marker called C5-OH (3-hydroxyisovaleryl carnitine) [8].
- Next Steps: An elevated C5-OH result is not a final diagnosis. It is a signal that more specific testing is needed, such as urine organic acid tests or genetic testing, to confirm if the baby has HLCS deficiency or a different condition [9][7].
In other cases, the diagnosis is made after a baby begins to show symptoms. Doctors refer to two main types based on when these signs appear:
- Neonatal-Onset: This is the most common form. Symptoms usually appear within hours to a few weeks after birth [7]. Early signs may include feeding difficulties, vomiting, extreme sleepiness (lethargy), or poor muscle tone (feeling “floppy”) [10][3].
- Late-Onset: This form appears later in infancy or childhood [11]. It may be triggered by a common illness, like a cold or the flu, which puts extra stress on the body’s metabolism [12][13].
The Power of Biotin
The most reassuring fact about HLCS deficiency is how effectively it often responds to treatment. Biotin supplementation is the primary treatment, and for many children, it works remarkably well [6].
When started early—ideally before a major metabolic crisis or neurologic injury occurs—pharmacologic doses of oral biotin can help normalize the body’s chemistry very quickly [10]. Research has shown that:
- Clinical symptoms and laboratory markers often improve significantly after starting treatment [10][14].
- Many children treated early achieve stable health and near-normal development [3].
- While most children with this condition go on to have normal intelligence and physical growth, outcomes depend heavily on the age at treatment, disease severity, and residual enzyme activity [3][4].
Moving Forward
While the diagnosis is lifelong, it is manageable. Your medical team will include a metabolic specialist (a doctor who specializes in how the body uses energy) and a genetic counselor. They will help you establish a routine for daily biotin and create a plan for what to do when your child gets sick, as illness can sometimes cause a temporary metabolic “flare-up” [12]. Ordinary developmental surveillance will be a standard part of their pediatric care.
The initial period after diagnosis is often the hardest. As you learn the routine and see your baby thrive on treatment, the “new normal” will begin to feel more manageable [1]. Many parents find that the initial fear is replaced by a sense of empowerment once they see how a vitamin supplement can make such a profound difference in their child’s health [15].
Common questions in this guide
Does an elevated C5-OH result mean my baby has HLCS deficiency?
What symptoms can appear with HLCS deficiency?
How does biotin treatment help a child with HLCS deficiency?
What is the outlook for a child diagnosed with HLCS deficiency?
What should I do if my child with HLCS deficiency becomes ill?
Which specialists manage HLCS deficiency?
How will doctors know whether HLCS treatment is working?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Was my baby diagnosed through newborn screening or because they started showing symptoms?
- 2.Does my baby have the neonatal-onset or late-onset form of this condition?
- 3.What specific tests were used to confirm the diagnosis?
- 4.Now that we have started biotin, how soon should we expect to see metabolic stability?
- 5.How will we monitor my child's growth and development to ensure the treatment is working?
- 6.Can you explain the genetic inheritance of HLCS and what it means for our family?
- 7.Who should I call first if my baby seems less active or isn't feeding well?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (15)
- 1
Parental experience and information needs following a positive newborn screening test-based neonatal diagnosis of a chronic condition: an integrative review.
Luck P, -Schmid JP, Naef R, et al.
International journal of nursing studies advances 2026; (11()):100646 doi:10.1016/j.ijnsa.2026.100646.
PMID: 42603951 - 2
Uncertainties experienced by parents of children diagnosed with severe combined immunodeficiency through newborn screening.
Raspa M, Kutsa O, Andrews SM, et al.
European journal of human genetics : EJHG 2024; (32(4)):392-398 doi:10.1038/s41431-023-01345-5.
PMID: 36973394 - 3
Clinical, biochemical, and genetic analysis of 28 Chinese patients with holocarboxylase synthetase deficiency.
Ling S, Qiu W, Zhang H, et al.
Orphanet journal of rare diseases 2023; (18(1)):48 doi:10.1186/s13023-023-02656-y.
PMID: 36890565 - 4
Holocarboxylase Synthetase Deficiency: Clinical, Biochemical and Molecular Findings in Five Malaysian Patients Including a Newborn Presenting as Collodion Baby.
Ting SL, Yakob Y, Sani HA, et al.
JIMD reports 2025; (66(2)):e70006 doi:10.1002/jmd2.70006.
PMID: 40051682 - 5
Holocarboxylase Synthetase: A Moonlighting Transcriptional Coregulator of Gene Expression and a Cytosolic Regulator of Biotin Utilization.
León-Del-Río A, Valadez-Graham V, Gravel RA
Annual review of nutrition 2017; (37()):207-223 doi:10.1146/annurev-nutr-042617-104653.
PMID: 28564555 - 6
Holocarboxylase synthetase deficiency: pathogenesis, clinical features, diagnosis, treatment, and research prospects.
ZeZhao J, Ablimit A
European journal of pediatrics 2026; (185(7)).
PMID: 42324336 - 7
Holocarboxylase synthetase deficiency pre and post newborn screening.
Donti TR, Blackburn PR, Atwal PS
Molecular genetics and metabolism reports 2016; (7()):40-4 doi:10.1016/j.ymgmr.2016.03.007.
PMID: 27114915 - 8
Elevated C5-hydroxy acylcarnitine in an infant girl as a result of holocarboxylase synthetase deficiency.
Nelson AT, Jones PM, Cao J
Clinica chimica acta; international journal of clinical chemistry 2024; (560()):119747 doi:10.1016/j.cca.2024.119747.
PMID: 38788890 - 9
Evaluation of Newborn Screening for Diseases Using C5-OH as a Marker: Systematic Review of the Literature and Evaluation of 17 Years of C5-OH Screening in the Netherlands.
Aukes R, Albersen M, Boelen A, et al.
Journal of inherited metabolic disease 2025; (48(5)):e70088 doi:10.1002/jimd.70088.
PMID: 40937535 - 10
Dramatic Clinical Improvement With Biotin Mega-Dose Therapy in a Neonate With Holocarboxylase Synthetase Deficiency.
Kim SW, Lee HJ, Choi N, et al.
Molecular genetics & genomic medicine 2024; (12(8)):e70002 doi:10.1002/mgg3.70002.
PMID: 39194177 - 11
Case report: Two siblings with very late onset of holocarboxylase synthase deficiency and a mini-review.
Gaschignard M, Domenach L, Lamireau D, et al.
Frontiers in genetics 2024; (15()):1249480 doi:10.3389/fgene.2024.1249480.
PMID: 39391064 - 12
Impaired glucose homeostasis and a novel HLCS pathogenic variant in holocarboxylase synthetase deficiency: a report of two cases and brief review.
Wu HR, Chen KJ, Hsiao HP, Chao MC
Journal of pediatric endocrinology & metabolism : JPEM 2020; (33(11)):1481-1486.
PMID: 32841162 - 13
Successful pregnancy and childbirth without metabolic abnormality in a patient with holocarboxylase synthetase deficiency.
Meguro M, Wada Y, Kisou Y, et al.
Molecular genetics and metabolism reports 2022; (33()):100923 doi:10.1016/j.ymgmr.2022.100923.
PMID: 36245960 - 14
Case report of holocarboxylase synthetase deficiency (late-onset) in 2 Chinese patients.
Xiong Z, Zhang G, Luo X, et al.
Medicine 2020; (99(18)):e19964 doi:10.1097/MD.0000000000019964.
PMID: 32358368 - 15
A qualitative study on the perspectives of mothers who had been diagnosed with primary carnitine deficiency through newborn screening of their child.
van den Heuvel LM, Kater-Kuipers A, van Dijk T, et al.
Orphanet journal of rare diseases 2023; (18(1)):134 doi:10.1186/s13023-023-02735-0.
PMID: 37268964
This page is for informational purposes only and does not constitute medical advice about your child's HLCS deficiency. Your child's metabolic specialist and pediatric team should interpret test results and guide biotin treatment and sick-day care.
Get notified when new evidence is published on Holocarboxylase synthetase deficiency.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.